Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01615042 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Lenalidomide in Patients With Acute Leukemia
A Phase 1 study, sponsored by Mehrdad Abedi, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01615042 is a Phase 1 study that was terminated before completion, run by Mehrdad Abedi, MD. The registered enrollment target is 6 participants.
The verdict
NCT01615042, a Phase 1 study, was terminated before completion, sponsored by Mehrdad Abedi, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Lenalidomide is a drug that alters the immune system and it may also be directly toxic to tumor. Therefore, in theory, it may reduce or prevent the growth of cancer cells or directly kill them. We will be studying how lenalidomide can be used to decrease bone marrow blast cells in preparation for a bone transplant.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01615042
The ClinicalTrials.gov registry entry for NCT01615042 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mehrdad Abedi, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT01615042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01615042 about?
NCT01615042 is a clinical study titled "Phase I Study of Lenalidomide in Patients With Acute Leukemia". Lenalidomide is a drug that alters the immune system and it may also be directly toxic to tumor. Therefore, in theory, it may reduce or prevent the growth of cancer cells or directly kill them. We will be studying how lenalidomide can be used to decrease bone marrow blast cells in preparation for a ...
What is the current status of trial NCT01615042?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-08. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01615042?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01615042?
This trial is sponsored by Mehrdad Abedi, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.